Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:TROV

Cardiff Oncology (TROV) Stock Price, News & Analysis

Cardiff Oncology logo

About Cardiff Oncology Stock (NASDAQ:TROV)

Advanced Chart

Key Stats

Today's Range
$4.51
$4.86
50-Day Range
$1.19
$24.71
52-Week Range
$0.70
$3.46
Volume
856,957 shs
Average Volume
648,892 shs
Market Capitalization
$50.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Receive TROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

TROV Stock News Headlines

Why Buffett and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
Cardiff Oncology Reports Positive Q3 2024 Results and Clinical Progress
Cardiff Oncology publishes onvansertib combination data in journal
See More Headlines

TROV Stock Analysis - Frequently Asked Questions

Cardiff Oncology, Inc. (NASDAQ:TROV) posted its quarterly earnings data on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. Cardiff Oncology had a negative net margin of 3,688.31% and a negative trailing twelve-month return on equity of 202.00%.

Shares of Cardiff Oncology reverse split before market open on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
2/27/2020
Today
2/25/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TROV
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-16,410,000.00
Net Margins
-3,688.31%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$0.94 per share

Miscellaneous

Free Float
N/A
Market Cap
$50.21 million
Optionable
Not Optionable
Beta
1.04
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:TROV) was last updated on 2/25/2025 by MarketBeat.com Staff
From Our Partners